Stability of Gentamicin and Tobramycin in Concentrate Solutions for Automated Peritoneal DialysisNance K.S.a · Matzke G.R.b
aCollege of Pharmacy, Xavier University of Louisiana, New Orleans, La.; bDrug Evaluation Unit, Regional Kidney Disease Program, Hennepin County Medical Center, and College of Pharmacy, University of Minnesota, Minneapolis, Minn., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Stability of gentamicin and tobramycin in 30 and 50% dextrose peritoneal dialysate concentrate (PDC) fluids was determined at room temperature. All solutions were prepared and stored at 23 °C and aliquots were obtained at 0, 1, 2, 4, 8, 12, 24, and 48 h. A degradation rate constant Kdeg was calculated from the concentration time curve of each solution. The length of time required for the gentamicin and tobramycin concentrations to decline to 90% of the initial concentration (t90) was also calculated. The Kdeg of gentamicin in all solutions was less than the Kdeg of tobramycin. The Kdeg increased markedly for gentamicin and tobramycin as the dextrose concentration increased in the PDC. Gentamicin is stable in the 30 and 50% PDC for at least 24 h at 23 °C. Tobramycin, however, demonstrated more than a 10% loss of activity in some PDC solutions. If tobramycin is to be added to PDC, especially the 50% dextrose solution, it should be used within 12 h after admixture.
© 1984 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.